Uncategorized
FDA approves Avedro’s cross-linking system for corneal ectasiafollowing refractive surgery
The FDA has approved the KXL system and two photoenhancers for the treatment of corneal ectasia following refractive surgery, according to an Avedro press release. The KXL system and the two photoenhancers, Photrexa 0.146% (riboflavin 5’-phosphate ophthalmic solution) and Photrexa Viscous 0.146% (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), previously received FDA approval in April for the treatment of progressive keratoconus.